

Yingke Biopharmaceutical



A benchmark enterprise of high-end complex drug products boosted by innovation

Love life & Love health

Part I

Company Profile


➤➤ Profile of the Group Company

Jiangsu Yingke Biopharmaceutical Co., Ltd. was founded in 2011 and located in Taizhou, Jiangsu Province. **Driven by innovation, it has become a benchmark enterprise in China's pharmaceutical industry of high-end complex drug products.**



Dedicated to **research, development, manufacturing and commercializing of complex emulsions, topical drug products, oral drug products for gastroscopy examination and innovative long-acting complex drug products.**

Profile of the Group Company



Profile of the Group Company

Taizhou. China



Yingke Biopharmaceutical

Manufacturing site
R&D institute

Yangzhou. China



Mingde Pharmaceutical

Manufacturing site

Sichuan. China



Yingke Haikun

R&D institute



Profile of the Group Company

Scale

2 FDF production sites

2 R&D institutes

Capacity

63M ampoules injectable(SVP)

9M packs injectable(LVP)

8M ointment

3M liniment

6M highly potent drops

ANDA Products

4+ Launched

16+ Registered

26+ under development

Yingke Biopharmaceutical



- China NMPA inspected facility
- Ready for US FDA/EU or other authorities inspections

- 11 Mfg lines of different dosage forms:
 - small-volume injection workshop
 - large-volume injection workshop (2)
 - soft capsule drug product workshop
 - oral liquid drug product workshop (3)
 - ointment workshop/gel workshop
 - liniment workshop
 - highly potent cream workshop
 - API workshop



Mingde Pharmaceutical



- China NMPA inspected facility
- Ready for US FDA/EU or other authorities inspections

- 3 Mfg lines of different dosage forms:
 - small-volume injection workshop
 - three-chamber bag large-volume workshop/
liquid-liquid double-chamber bag workshop
 - highly potent drops workshop



R&D institutes : Yingke Taizhou & Yingke Haikun



核心成就 ACHIEVEMENT

More than 30 years of managing projects for generic and innovative complex drug products

International CRO & CDMO



Yingke Tianlu & Yingke Wenyao & Yingke Beijing



➤ Hangzhou


➤ Shanghai

➤ Beijing

- Cross-border Commerce
- International Strategic Layout
- Business Collaboration



Technical Team




	Researchers	PhD	Master	Bachelor
Taizhou R&D	52	3	20	29
Sichuan R&D	53	/	29	24
Total	105	3	49	53
Ratio	/	3%	47%	50%



➤➤ Domestic sales



Fast growing sales (CNY)



➤➤ Domestic sales

Domestic sales team

150+ sales representatives



2500+ hospitals(level II and level III) and 5,000+ community-level medical institutions with 5800+ distributors and wholesalers

Founder



Mr. Hai Li

01

Director in the Council of the Chinese Pharmaceutical Society

02

Executive Member in the Executive Committee of Jiangsu Federation of Industry and Commerce

03

Executive Director in the Chinese Society of Biotechnology

Experience in drug formulation & sales management → industrialization of complex drug products → focusing on industry policies & integrating industry resources → in drug development strategy combining generic and innovation

Managing/Technical Team

The core technical team possesses nearly 30 years of experience in industrialization & commercialization of complex drug products within segmented fields.



Mr. Qi Sha
CEO



Mr. Cunqiang Gao
Mingde GM



Mr. Lichun Wang
President
CTO



**Dr. (Oxon)
Jingda Yin**
Vice-president



Mr. Jian Mou
VP of Sales



Dr. Bao Teng
Vice-president



Dr. Zhaotang Ma
Vice-president



Mr. Xiubin Hao
Strategic Director

Technical consultants



Dr. Hong Gu

PHD in Organic Chemistry, USA.
Formerly President of operations at Wuxi Apptec
Research field:
Development of raw materials and high-end complex preparations



Mr. Yueyun Chen

Technical adviser
Extensive experience in quality management of highly complex emulsions



Dr. Jun He


Senior R&D Director,
PHD in Pharmacy,
Fields of Study: Research on New Injection and Drug Delivery Systems.



Pro. Shengjun Mao

Professor of Pharmacy, Sichuan University
Research Fields:
1. New drug delivery system and its application foundation.
2. Research on innovative drugs for complex preparations.

Global BD and Regulatory Affairs Team

- A highly experienced international RA team headed by Dr. Jingda Yin (**University of Oxford**).
- >200 R&D projects;
- >100 Registered countries;
- >200 Global MA/ANDA approvals;
- 9 US ANDAs in 2023;
- 14 US ANDAs in 2024;  **Top in China**
- Fully understanding the global regulations, such as FDA, EMA, MHRA, TGA and HC, etc.



Jingda Yin

- **Vice-president of Global BD and Regulatory Affairs**
- **University of Edinburgh, Medicinal and Biological Chemistry, Bachelor's and Master's Degree (First Class Honours)**
- **University of Oxford, Organic Chemistry, D.Phil**
- Pfizer Pharmaceuticals UK R&D Department, Synthetic Researcher
- 13 years of experience in R&D of generic and innovative drugs, global registration and global BD;
- ~20 GMP inspections of US and EU.



Lili Jia

• Director of Global Regulatory Affairs

- 15 years of experience in R&D of generic and innovative drugs, global registration;
- >50 Registered countries;
- >100 Global MA/ANDA approvals;
- ~10 GMP inspections of US and EU.



Qichao Li

• Manager of Global Regulatory Affairs

- 10 years of experience in international drug registration;
- >50 Global MA/ANDA approvals;
- ~10 GMP inspections of US and EU.



Juan Wang

• Specialist of Global Regulatory Affairs


- 9 years of experience in international drug registration;
- ~30 Global MA/ANDA approvals;
- ~5 GMP inspections of US and EU.

Part II

Technology Platform

➤➤ Pipeline Layout and Technical Platform

Relying on **the emulsion technology platform**, Yingke Biopharmaceutical builds **a national innovative drug product platform** by laying out products around **characteristic sales terminals**.



➤ Main Marketed Products



1 Medium/long Chain Lipid Injectable Emulsion(C6-24)



2 Propofol Medium/long Chain Lipid Injectable Emulsion



3 Propofol Lipid Injectable Emulsion

- Indications: parenteral nutrition and/or essential fatty acid deficiency .
- Listed in national medical insurance and essential drug directories
- Advantages : **Domestic Market size of nearly 45 million bags (bottles)/year.**
- **The first generic for domestic market**
- **Pass equivalency evaluation**

- Indication: Intravenous general anesthesia induction drug
- Listed in national medical insurance—**Domestic Market size of nearly 30 million units/year**
- **The drug was selected as the Fourth Batch of National Centralized Procurement Catalogue on February 3, 2021 .**
- **First domestic company to pass equivalency evaluation**

- Indication: Intravenous general anesthesia induction drug
- Listed in national medical insurance and essential drug directories—**Domestic Market size of nearly 120 million units/year**
- **The drug was selected as the Ninth Batch of National Centralized Procurement Catalogue on November 6, 2023.**
- **Pass equivalency evaluation - Class 4 new drugs.**

➤➤ Main products



Amino acids (17), Glucose (19%) and Lipid Injectable Emulsion

Product Features

Comprehensive nutrition, rapid and long-lasting energy supply
Effectively promote protein synthesis and reduce infection

Indications

This product is indicated for adult patients requiring parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated.

Amino acids (17), Glucose (11%) and Lipid Injectable Emulsion

Product Features

Comprehensive nutrition, reasonable proportion
Synergistic energy supply and promotion of protein synthesis

Indications

This product is indicated for adult patients requiring parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated.

➤➤ Main products



Part III

Business opportunity

Our Business

- Collaboration for global registration, marketing and sales
- Licensing in/ out
- Co-development
- Providing CDMO service



Contact us

- E-mail: yinjingda@jsykswzy.cn



Thanks



love life & love health